BioLineRx (BLRX) Assets Average (2011 - 2026)

BioLineRx's Assets Average history runs 15 years deep, the most recent figure standing at $40.4 million for Q4 2025.

• In Q4 2025, Assets Average fell 11.94% year-over-year to $40.4 million; the TTM figure through Dec 2025 stood at $40.4 million (down 11.94% YoY), while the FY2025 annual figure was $39.9 million, down 22.39% from the prior year.
• Assets Average for Q4 2025 stood at $40.4 million, down from $41.5 million in the prior quarter.
• The five-year high for Assets Average was $89.1 million in Q3 2021, with the low at $40.4 million in Q4 2025.
• The 5-year median for Assets Average is $61.2 million (2023), against an average of $63.3 million.
• The sharpest annual moves came in 2021 and 2025: Assets Average soared 80.33% in 2021, then fell 29.2% in 2025.
• BioLineRx's Assets Average stood at $84.1 million in 2021, then retreated by 6.08% to $79.0 million in 2022, then dropped by 26.12% to $58.4 million in 2023, then slipped by 21.52% to $45.8 million in 2024, then dropped by 11.94% to $40.4 million in 2025.
• Business Quant data shows BLRX's Assets Average at $40.4 million in Q4 2025, $41.5 million in Q3 2025, and $43.4 million in Q2 2025.